Axis Securities has set a target price of Rs 2,500 on Lupin, showing an upside potential of around 27% from the current market prices.
“New launches in the U.S. market, such as Darunavir and Spiriva, have gained market shares of up to 30% and 25%, respectively. The recent approval for gMegabran has the potential to contribute $50 Mn in annual incremental sales. Additionally, approvals for Tolvaptan (market size $287 Mn) and Xyway (market size $958 Mn with 180-day exclusivity) could drive growth in the second half. The company has a robust product pipeline, which includes Cyanocobalamin, Diazepam Gel, Varenicline, Bromfenac, Glucagen, and Risperidone, among others,” it said.
